Cell-permeable peptide inhibitors of the JNK signal transduction pathway
OwnerChristophe Bonnyinventor
Life of this patent
Estimating the term…
Abstract
The invention provides cell-permeable peptides that bind to JNK proteins and inhibit JNK-mediated effects in JNK-expressing cells.
Claims22
A method of inhibiting neuronal cell damage in a subject, comprising administering to the subject prior to identification of said cell damage a composition comprising a peptide selected from the group consisting of the amino acid sequence of SEQ ID NO:
- 1-6, 11-16 and 23-26.
A method of inhibiting an ischemic or reperfusion related injury in a subject, comprising administering to the subject prior to identification of symptom of ischemia or reperfusion injury a comprising stroke, amyotrophic lateral sclerosis, epilepsy, multiple sclerosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, neurolathyrism, human immunodeficiency virus dementia, or autoimmune disease.
A method of inhibiting neuronal cell death in a mammal, comprising administering to said mammal comprising a peptide selected from the group consisting of the amino acid sequence of SEQ ID NO:
- 1-6, 11-16 and 23-26, wherein said mammal is suffering from or at risk of developing a neuronal disorder.
A method of treating a neuronal disorder, comprising administering to said mammal a composition comprising a peptide selected from the group consisting of the amino acid sequence of SEQ ID NO:
- 1-6, 11-16 and 23-26.
A method of inhibiting neuronal cell death, comprising contacting said cell with a composition comprising a peptide selected from the group consisting of SEQ ID NO:
- 1-6, 11-16 and 23-26.
Dependencies are inferred from the claim text.